28 related articles for article (PubMed ID: 6329508)
1. Diagnostic value of CT and MRI combined with serum LDH, NSE, CEA, and MYCN in pediatric neuroblastoma.
Hao J; Sang J; Xu X; Bao A
World J Surg Oncol; 2023 Aug; 21(1):251. PubMed ID: 37592273
[TBL] [Abstract][Full Text] [Related]
2. [Serum neuron-specific enolase (NSE) in patients with small cell lung cancer--comparison with carcinoembryonic antigen (CEA)].
Kawahara M; Furuse K; Arai R; Tsuruta M; Kodama N; Hayashi S; Kiyota M; Kubota K; Mori T; Yamamoto S
Gan To Kagaku Ryoho; 1987 Jan; 14(1):146-51. PubMed ID: 3026253
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
4. Comparative studies of CAM 123-6 and carcinoembryonic antigen for the serological detection of pulmonary adenocarcinoma.
Kohno N; Hirasawa Y; Kondo K; Fujioka S; Fujino S; Abe M; Yokoyama A; Hiwada K; Watanabe K; Nishimura J
Cancer Detect Prev; 1997; 21(2):124-8. PubMed ID: 9101072
[TBL] [Abstract][Full Text] [Related]
5. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
6. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
7. Multiple sequential biomarkers in monitoring patients with carcinoma of the lung.
Aroney RS; Dermody WC; Aldenderfer P; Parsons P; McNitt K; Marangos PJ; Whitacre MY; Ruddon RW; Wiernik PH; Aisner J
Cancer Treat Rep; 1984 Jun; 68(6):859-66. PubMed ID: 6329508
[TBL] [Abstract][Full Text] [Related]
8. [Tumor markers in lung cancer].
Niho S; Shinkai T
Gan To Kagaku Ryoho; 2001 Dec; 28(13):2089-93. PubMed ID: 11791391
[TBL] [Abstract][Full Text] [Related]
9. Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment.
Hiraki A; Ueoka H; Yoshino T; Chikamori K; Onishi K; Kiura K; Bessho A; Mimoto J; Date H; Ando A; Shimizu N; Harada M
Oncol Rep; 1999; 6(1):75-80. PubMed ID: 9864405
[TBL] [Abstract][Full Text] [Related]
10. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
Ebert W; Muley T; Drings P
Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
[TBL] [Abstract][Full Text] [Related]
11. Role of biological markers and probes in lung carcinomas.
Dorreen MS
Bull Eur Physiopathol Respir; 1986; 22(2):137-46. PubMed ID: 2871878
[TBL] [Abstract][Full Text] [Related]
12. [Tumor markers, significance for clinical diagnosis].
Gropp C
Pneumologie; 1991 Apr; 45(4):137-9. PubMed ID: 1876589
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]